Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Publication

Article

February 22, 2019

CURE

Winter 2019
Volume18
Issue 1

Findings Link Diet Soda With Reduced Risk of Colon Cancer Recurrence

Author(s):

Beth Fand Incollingo

A daily dose of diet soda may help protect survivors of colon cancer from disease recurrence and death.

A daily dose of diet soda may help protect survivors of colon cancer from disease recurrence and death.

Survivors of stage 3 colon cancer undergoing chemotherapy after sur­gery benefited from drinking artificially sweetened beverages, according to study results published in July 2018. Those who drank at least one 12-ounce serving a day had roughly half the risk of cancer recurrence or death compared with survivors who usually didn’t drink these beverag­es. Increased intake of artificially sweetened drinks was also associated with a statistically significant improvement in length of life.

Furthermore, replacing a daily 12-ounce serving of a sugary drink with an artificially sweetened one was associated with a 23 percent lower risk of cancer recurrence and mortality, Brendan J. Guercio, M.D., and col­leagues, reported in a paper in the journal PLOS ONE.

The study authors explored the potential connection between arti­ficially sweetened drinks and better health outcomes because they knew from previous findings that having an excess energy balance — related to, for instance, a sedentary lifestyle, diabetes or high intake of sugar-sweetened beverages — is associated with increased colon cancer recurrence and mortality. “We hypothesized that artificially sweetened beverage intake might reduce colon cancer recurrence by substituting for, and thereby reduc­ing, intake of high-calorie, sugar-sweetened alternatives,” they wrote.

The 1,108 survivors in the study reported their dietary and lifestyle habits, including intake of artificially sweetened beverages, by question­naire four months into chemother­apy treatment and six months after completing therapy. The findings of a benefit associated with artificial­ly sweetened beverages persisted even after researchers adjusted for factors that could affect the results, such as body mass index, physical activity, following Western eating patterns and dietary glycemic load, they wrote. Glycemic load refers to the amount a particular food raises the glucose level in a person’s blood; sugars and other carbohydrates tend to increase this number.

The scientists suggested that consumption of both categories of beverages should also be studied in people who have not developed colon cancer.

“Given the likelihood that individuals who consume artificially sweetened beverages following cancer diagnosis also consumed artificially sweetened beverages prior to cancer diagnosis, we can­not exclude the possibility that individuals who consume artificially sweetened beverages develop biologically less aggressive colon cancer tumors,” they wrote. “Future studies should examine artifi­cially sweetened beverage intake both before and after colon can­cer diagnosis in order to further elucidate the relationship between artificially sweetened beverage intake and colon cancer recurrence and mortality.”

Diet soda’s affect on initial colon cancer risk should be studied next, scientists say.

Articles in this issue

Positively Deleterious
Tutu Good
Paying it Forward: Donating Time in the Cancer Community
Hockey Player Announces His Cancer Is In Remission
Ginsburg Returns to Work During Recovery From Lung Surgery
Findings Link Diet Soda With Reduced Risk of Colon Cancer Recurrence
The Long Haul: Facing the Long-Term Side Effects of Testicular Cancer
The Long Haul: Facing the Long-Term Side Effects of Testicular Cancer
Should Patients Have to Pay for the Drugs They Helped Test?
Changing Our Standards
Sweet Surrender: Will Cutting Out Sugar Help You Prevent Cancer?
Beyond the Norm
Actor Bob Einstein Dies of Cancer
New Movie Tells Gilda Radner's Life Story
Read Between the Lines: Understanding Clinical Studies

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Eng.
Image of man with black hair.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Image of woman with blonde hair.
Image of Dr. Fakih.
Image of Doctor with blonde hair.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Scott Kopetz
Image of woman with black hair.
Related Content
Advertisement
Image of intestines
May 6th 2025

Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC

Ryan Scott
Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.
Dr. Dawn Mussallem in a bright yellow shirt and pink hat, both with breast cancer ribbons on it, showing off her medal at the finish line of The DONNA Foundaton marathon | Photo credit: The DONNA Foundation
May 18th 2023

Doctor, Cancer Survivor and Marathoner Goes the Distance for Her Patients: ‘Now I Can Just Give’

Alex Biese
Dr. Dawn Mussallem of the Mayo Clinic tells CURE®’s “Cancer Horizons” podcast about how surviving stage 4 non-Hodgkin’s lymphoma and being a heart transplant recipient helps her connect with her patients.
LUT014 improved rashes in patients with colorectal cancer undergoing anti-EGFR therapy: © stock.adobe.com.
May 1st 2025

BRAF Inhibitor Gel Improves Acne-Like Skin Rashes in Colorectal Cancer

Spencer Feldman
LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
The first patient with metastatic colorectal cancer has received TCMCB07 in a phase 2 trial to prevent weight loss in those undergoing chemotherapy: © stock.adobe.com.
April 18th 2025

First Patient with Colon Cancer Dosed in a Phase 2 Study of TCMCB07

Spencer Feldman
The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.
Image of Clinical trial text.
April 12th 2025

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

Alex Biese
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
Related Content
Advertisement
Image of intestines
May 6th 2025

Delving Into the Braftovi Plus Erbitux FDA Approval for BRAF+ mCRC

Ryan Scott
Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.
Dr. Dawn Mussallem in a bright yellow shirt and pink hat, both with breast cancer ribbons on it, showing off her medal at the finish line of The DONNA Foundaton marathon | Photo credit: The DONNA Foundation
May 18th 2023

Doctor, Cancer Survivor and Marathoner Goes the Distance for Her Patients: ‘Now I Can Just Give’

Alex Biese
Dr. Dawn Mussallem of the Mayo Clinic tells CURE®’s “Cancer Horizons” podcast about how surviving stage 4 non-Hodgkin’s lymphoma and being a heart transplant recipient helps her connect with her patients.
LUT014 improved rashes in patients with colorectal cancer undergoing anti-EGFR therapy: © stock.adobe.com.
May 1st 2025

BRAF Inhibitor Gel Improves Acne-Like Skin Rashes in Colorectal Cancer

Spencer Feldman
LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers.
Teri Greige with medals
February 16th 2023

The Sport of Cancer: How One Survivor Linked Ironman Training and Colorectal Cancer

Brielle Benyon
Teri Griege completed an Ironman triathlon in 2009, and less than a month later received a stage 4 colorectal cancer diagnosis. In this episode of Cancer Horizons, she shared her story.
The first patient with metastatic colorectal cancer has received TCMCB07 in a phase 2 trial to prevent weight loss in those undergoing chemotherapy: © stock.adobe.com.
April 18th 2025

First Patient with Colon Cancer Dosed in a Phase 2 Study of TCMCB07

Spencer Feldman
The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal cancer undergoing chemotherapy.
Image of Clinical trial text.
April 12th 2025

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

Alex Biese
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.